Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

Investors are expected to be cautious with TORNTPHARM, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.19200
forwardPE 35.30482
debtToEquity 42.18200
earningsGrowth 0.10800
revenueGrowth 0.07800
grossMargins 0.75894
operatingMargins 0.25786
trailingEps 56.38000
forwardEps 0.00000

The current ratio for TORNTPHARM is 1.192, indicating that the company can service its short-term debt using available cash and assets. This suggests TORNTPHARM has strong liquidity, with more than enough resources to meet its immediate financial commitments.
TORNTPHARM's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

TORNTPHARM's price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of TORNTPHARM's future.

Insider Transactions:

Insider Transactions for TORNTPHARM
Insider Transactions for TORNTPHARM


TORNTPHARM had 1 buy transactions, with market price of 3224.449951171875.During the review period, no buy transactions were executed.TORNTPHARM has seen more sells than buys at current price levels, which could point to a potential price drop. If this selling trend persists, it may indicate that investors are expecting further declines in the stock's value.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


The analysts' recent buy bias for TORNTPHARM indicates strong confidence in the stock's future performance. This could encourage more investors to view TORNTPHARM as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.